

Erratum to “Clinical Study on Nicotinamide Phosphoribosyl Transferase and *SIRT1* Level in Patients With Neutropenia After Chemotherapy for Lung Cancer”

[Shimane J Med Sci, Vol. 38, pp. 119-125, 2021]

Yukari TSUBATA¹⁾, Tomomi AKITA²⁾, Ryosuke TANINO¹⁾, Takamasa HOTTA¹⁾, Ayano TEZUKA²⁾, Misato KOBAYASHI¹⁾, Takae OKUNO¹⁾, Yohei SHIRATSUKI¹⁾, Akari TANINO¹⁾, Megumi HAMAGUCHI¹⁾, Chikamasa YAMASHITA²⁾, Takeshi ISOBE¹⁾

¹⁾*Division of Medical Oncology & Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Shimane University, 89-1 Enya-cho, Izumo, Shimane 693-8501, Japan*

²⁾*Department of Pharmaceutics and Drug Delivery, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-8510, Japan*

(Received October 14, 2021; Accepted November 22, 2021)

After publishing the above article, the publisher noticed that the table 1 legend was not printed correctly. We regret to inform you that we have made the following correction.

Table 1. Patient background variables and chemotherapy regimens

Patient number		N = 16
Median age (range)		68.5 (50-75)
Sex, male/female (%)		13(81.3) / 3(18.8)
ECOG PS (%)	0	5 (31.3)
	1	10 (62.5)
	2	1 (6.3)
Histology (%)	Adenocarcinoma	10 (62.5)
	Squamous cell carcinoma	5 (31.1)
	Adenosquamous carcinoma	1 (6.3)
Stage (%)	IV	2 (12.5)
	Postoperative setting	14 (87.5)
Chemotherapy regimen (n, %)		
CBDCA/S-1, CDDP/PEM/BEV (3, 18.8)		
CBDCA/PEM/BEV, CDDP/PEM, CDDP/GEM, CDDP/VNR (2, 12.5)		
CBDCA/PTX/BEV, CBDCA/nab-PTX (1, 6.3)		

BEV, bevacizumab; CBDCA, carboplatin; CDDP, cisplatin; ECOG PS, Eastern Cooperative Oncology Group Performance Status; GEM, gemcitabine; PEM, pemetrexed; PTX, paclitaxel; VNR, vinorelbine